Join our community of smart investors

Exploit this Aim investment company's chronic undervaluation

Its market capitalisation is half the value of one of its holdings, even though it has a winning formula for success
May 22, 2024
  • Annual pre-tax loss of $15.7mn
  • Portfolio has since surged in value
  • 66 per cent share price discount to spot NAV

Annual results from Aim investment company Tekcapital’s (TEK:10.75p) reveal a $14.2mn write-down caused by mark-to-market losses on holdings in two listed companies: Aim-traded respiratory medical device company Belluscura (BELL: 15.5p) and Innovative Eyewear (US:LUCY), the first company to deliver prescription glasses with Bluetooth technology. The markdowns reduced net asset value (NAV) by 17 per cent to $47.9mn after factoring in $5mn of equity raises.

However, the portfolio has since rocketed in value following the IPO of investee company MicroSalt (SALT:129p), a company that produces low-sodium salt (MicroSalt IPO highlights the value in Tekcapital’, 1 February 2024). MicroSalt’s share price has trebled since IPO, which means that Tekcapital’s 77.3 per cent stake is now worth $54.8mn (£43mn). Moreover, Tekcapital has recovered all last year’s fair value losses, and its latest portfolio valuation of $75mn (£59mn) comfortably exceeds the $55mn valuation in the 2022 accounts, too. Spot NAV is three times its market capitalisation of £21.3mn.

Earlier this month, MicroSalt was granted an important patent that strengthens its position in the low-sodium market as it looks to secure orders with multinational companies testing the product. The company appears to have a winning formula and one that should turn a business with a relatively fixed cost base profitable in due course, assuming management can secure deals with large fast-moving consumer goods (FMCG) customers. Tekcapital’s undervaluation is anomalous. Buy.

Special offer. Simon Thompson's books Successful Stock Picking Strategies and Stock Picking for Profit can be purchased online at www.ypdbooks.com at the special discounted price of £5 per book plus UK P&P of £4.95, or £10 for both books plus UK P&P of £5.75, subject to stock availability.

They include case studies of Simon’s market beating Bargain Share Portfolio companies outlining the characteristics that made them successful investments. Simon also highlights many other investment approaches and stock screens he uses to identify small-cap companies with investment potential. Full details of the content of the books can be viewed on www.ypdbooks.com.